Approved May 2001
Thyroid disease; Hypothyroidism
Diabetes / Endocrinology
Levoxyl has been approved for use as a replacement therapy for any form of diminished or absent thyroid function and as a means of suppressing pituitary secretion of TSH in euthyroid subjects to treat or prevent goiters. Levoxyl is available in tablet formulation, in 12 different color-coded strengths.
About 20 million Americans suffer from some form of thyroid disease and over 13 million subjects in the United States rely on hormone replacement therapy, which is usually taken for life, for treatment.
Levoxyl has been prescribed as a thyroid hormone replacement therapy for the past 13 years. Due to an FDA ruling in 1997, all companies manufacturing levothyroxine sodium drugs were required to submit new drug applications in order to continue marketing these products.
Adverse events associated with the use of levothyroxine sodium may include (but are not limited to) the following:
Levoxyl contains synthetic crystalline levothyroxine sodium, which is the principal hormone secreted by the thyroid gland. Thyroid hormones are designed to regulate the metabolic rate of most body tissues.
For additional information on Levoxyl, please visit Jones Pharma.
The Levoxyl drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.